NCT04929028 2026-04-13Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting40 enrolled
NCT05627635 2025-11-10FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerCity of Hope Medical CenterPhase 1/2 Active not recruiting20 enrolled